Vivex Biomedical, Inc.   Report issue

For profit Phase 3
Founded: Marietta GA United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT02932020
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

VIVEX Biologics, Inc. | Vivex Biomedical | Vivex Biomedical, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

amniotic fluid (1 trial)

Drugs in Other Trials (4)

allogen-li (1 trial)

levobupivacaine (chirocaine) (1 trial)

methylprednisolone (medrol) (1 trial)

viagenex max (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Tendon Entrapment (Phase 3)

Tenosynovitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5